Ovarian Cancer News & Features
Overweight or obese patients with ovarian cancer are typically given lower per-pound chemotherapy doses to reduce toxic side effects, which could impact their survival chances.
Researchers have found that spending more leisure time sitting was associated with an increased risk for developing cancer in women.
Researchers have found that the experimental drug fostamatinib, combined with the chemotherapy drug paclitaxel, may overcome ovarian cancer cells' resistance to paclitaxel.
The discovery of three genetic variants associated with mucinous ovarian carcinomas (MOCs) offers the first evidence of genetic susceptibility in this type of ovarian cancer.
Researchers have identified a molecule that may play a central role in chemotherapy resistance in patients with the most common ovarian cancer.
Ovarian Cancer Clinical Trials
- Model shows how cancerous tumors manipulate blood-vessel growth
- Universal health literacy precautions recommended to assist patient understanding
- Likelihood of lung cancer screening update
- Generic meds may boost survival in some early breast cancers
- State regulations associated with late-stage cancer diagnoses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|